Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05057494
Title A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (MAJIC)
Recruitment Not yet recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Obinutuzumab + Venetoclax

Acalabrutinib + Venetoclax

Age Groups: adult | senior
Covered Countries USA | FRA | ESP


No variant requirements are available.